Promoter Hypermethylation of Tumor-Suppressor Genes \( p16^{INK4a} \), RASSF1A, TIMP3, and PCQAP/MED15 in Salivary DNA as a Quadruple Biomarker Panel for Early Detection of Oral and Oropharyngeal Cancers

Chamikara Liyanage 1, Asanga Wathupola 1, Sanjayan Muraleetharan 1, Kanthi Perera 2, Chaminde Punyadeera 3,4 and Preethi Udagama 1,*

1 Department of Zoology and Environment Sciences, University of Colombo, Colombo 03 00300, Sri Lanka; chamikara1@live.com (C.L.); awathupola@zoology.cmb.ac.lk (A.W.); muraly_3@yahoo.com (S.M.)
2 National Cancer Institute of Sri Lanka, Maharagama 10280, Sri Lanka; kanthiperera3@gmail.com
3 The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD 4059, Australia
4 Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane, QLD 4102, Australia; chaminde.punyadeera@qut.edu.au

* Correspondence: preethi@zoology.cmb.ac.lk; Tel.: +94-71-441-6050; Fax: +94-11-250-3148

Received: 17 March 2019; Accepted: 8 April 2019; Published: 12 April 2019

Abstract: Silencing of tumor-suppressor genes (TSGs) by DNA promoter hypermethylation is an early event in carcinogenesis; hence, TSGs may serve as early tumor biomarkers. We determined the promoter methylation levels of \( p16^{INK4a} \), RASSF1A, TIMP3, and PCQAP/MED15 TSGs in salivary DNA from oral cancer (OC) and oropharyngeal cancer (OPC) patients, using methylation-specific PCR coupled with densitometry analysis. We assessed the association between DNA methylation of individual TSGs with OC and OPC risk factors. The performance and the clinical validity of this quadruple-methylation marker panel were evaluated in discriminating OC and OPC patients from healthy controls using the CombiROC web tool. Our study reports that RASSF1A, TIMP3, and PCQAP/MED15 TSGs were significantly hypermethylated in OC and OPC cases compared to healthy controls. DNA methylation levels of TSGs were significantly augmented by smoking, alcohol use, and betel quid chewing, indicating the fact that frequent exposure to risk factors may drive oral and oropharyngeal carcinogenesis through TSG promoter hypermethylation. Also, this quadruple-methylation marker panel of \( p16^{INK4a} \), RASSF1A, TIMP3, and PCQAP/MED15 TSGs demonstrated excellent diagnostic accuracy in the early detection of OC at 91.7% sensitivity and 92.3% specificity and of OPC at 99.8% sensitivity and 92.1% specificity from healthy controls.

Keywords: oral cancer; oropharyngeal cancer; tumor-suppressor genes; promoter hypermethylation

1. Introduction

Oral and oropharyngeal squamous cell carcinomas (OSCC and OPSCC) are the most common types of head and neck squamous cell carcinoma (HNSCC) ranked as the sixth most common cancer type and the eighth most common cause of cancer death worldwide [1,2]. Annually, cancers in the lip and oral cavity account for more than 130,900 new cases and 74,500 deaths for males in developing countries [2]. Oral cancer (OC) and oropharyngeal cancer (OPC) record a high age-standardized incidence rate (ASIR) in Sri Lanka [3]. Despite the advances in treatment, no significant improvement was witnessed in the five-year survival rate of OC patients in Sri Lanka over the past several decades,
where survival remains at 50–55% [4,5]. Tobacco smoking, alcohol consumption, and betel quid chewing are considered as established risk factors for OC and OPC, while there is a dramatic increase in the incidence of OPC attributable to human papillomavirus (HPV) infections [6,7].

Cancer is a disease which evolves from the successive accumulation of genetic and epigenetic alterations [8]. Hypermethylation of cytosine/guanine (CpG) islands in the promoter regions of tumor-suppressor genes (TSGs) cause loss of expression leading to cancer initiation [9]. Research reported that many TSGs are epigenetically silenced by promoter hypermethylation in the OC cell genome [10–13]. Increasing evidence is mounting that age, race, and tobacco, alcohol, and betel quid carcinogens are capable of inducing promoter hypermethylation in TSGs, which may ultimately induce oral malignancies [14–17].

Successful screening and surveillance approaches consider the collection of genomic material using minimally invasive approaches. Aberrant DNA methylation can be detected in DNA from serum, sputum, bronchial lavage fluid, urine, and ductal fluids from patients with many different types of cancers [10,18–21]. Saliva is a complex and important body fluid which is already used for screening cancers in the upper aero-digestive tract, as well as OC and OPC [10,22–26]. Early screening of oral lesions using salivary biomarkers is very promising because saliva is in direct contact with the oral mucosa and cancerous lesions with a low background of inhibitory substances [27]. Methylation array analysis of DNA allowed interrogating cancer-related genes that are specific and sensitive for the early detection of cancer [28]. The methylation-specific polymerase chain reaction (MS-PCR) method provides a highly sensitive, economical, and time-efficient method to detect relatively low concentrations of methylated sequences in salivary rinses [29–32].

Early detection efforts using molecular markers have the potential to decrease the disease burden and play a significant role in the successful clinical treatment of any cancer [27]. In the current study, we aimed to determine whether promoter methylation of \textit{p16\textsuperscript{INK4a}}, \textit{RASSF1A}, \textit{TIMP3}, and \textit{PCQAP/MED15} TSGs in DNA derived from saliva can serve as a diagnostic marker panel in the early detection of OC and OPC. This study focused on two objectives: (1) to determine the promoter methylation levels of TSGs using the MS-PCR method combined with densitometry analysis to assess their association with established and emerging risk factors of OC and OPC, and (2) to evaluate the clinical performance of this methylation marker panel in discriminating OC and OPC subjects from a healthy control cohort using CombiROC analysis.

2. Materials and Methods

2.1. Ethical Approval

This study received the consent of the Ethics Review Committee (ERC) of the Faculty of Medicine, University of Colombo, Sri Lanka (EC-16-125) for the collection of biological samples and socio-economic and demographic details of OC and OPC patients, and of healthy controls.

2.2. Study Subjects and Data Collection

Newly enrolled, treatment-naïve cancer patients with primary cancer in the oral cavity \((N = 54)\) and oropharynx \((N = 34)\) or patients with loco-regional metastasis with oral/oropharyngeal origin who gave voluntary consent were enrolled in this study as case/test subjects, from the National Cancer Institute, Sri Lanka. An interviewer-administered questionnaire was used to collect demographic data and risk factors associated with OC and OPC. Medical information of patients was retrieved from their pathology report with the pathological staging of the tumor and histopathological classification of the tumor grade. Age- and gender-matched healthy individuals \((N = 60)\) with no personal history of cancer were recruited as normal healthy control subjects.
2.3. Sample Collection

Saliva samples from case and control subjects were collected at baseline. Patients who volunteered to take part in the study were requested to sit in a comfortable upright position. After rinsing the mouth with saline water to remove food debris, subjects were asked to tilt their head down for 5 min to pool saliva in the mouth. A volume of 2 mL of saliva was collected into sterile containers. Dry ice was used to transport sample containers. Samples were centrifuged at 1200 \( \times \) g for 10 min at 4 °C to isolate cellular pellet collection [11,33,34]. Sample collection was carried out for 12 months. DNA extraction was performed within seven days of the date of sample collection.

2.4. DNA Extraction and Human DNA Confirmation

The DNeasy Blood and Tissue kit (QIAGEN, Hilden, Germany; Cat no: 69504) was used according to the manufacturer’s instructions to extract DNA from cell pellets of saliva samples. PC03 and KM38 primers were used on extracted DNA samples to amplify a 167-bp region of the human \( \beta \)-globin housekeeping gene to confirm the presence of human DNA [35]. PCR-positive samples were used for further analyses.

2.5. HPV-L1 DNA Detection

GP5+/GP6+ primer sequences were used to amplify a 150-bp region of the HPV-L1 gene [36] (Table 1). The reaction mixture was prepared with the Promega GoTaq Flexi DNA Polymerase PCR kit. Each PCR reaction contained 2.5 mM MgCl\(_2\), 0.2 mM deoxyribonucleotide triphosphate (dNTP), and 0.5 \( \mu \)M primers. PCR conditions were set up as follows: initial denaturation at 94 °C for 3 min, 40 cycles of denaturation at 94 °C for 45 s, primer annealing at 42 °C for 45 s, primer extension at 72 °C for 45 s, and a final extension at 72 °C for 5 min. Each PCR reaction panel included an HPV-positive control and a negative PCR control. PCR products were visualized on 2% agarose gels with ethidium bromide (EtBr) staining [37].

Table 1. Primer sequences used in the study.

| Gene          | Primer Sense (5’–3’)                | Primer Antisense (5’–3’)               | PCR Product Size (bp) |
|---------------|-------------------------------------|----------------------------------------|-----------------------|
| \( \beta \)-globin | PC03: ACACAACGTGTGTTACTAGC | KM38: TGTCCTCCTAAACCTGTTTG | 167                   |
| HPV-L1        | GP5+: TTTTGTACTGTGTTAGATACACTAC    | GP6+: GAAAATAAACTGTTAATACATT          | 150                   |
| p16\( ^{R/K} \)(M) | GAGGAAAGAAGAGAGGAGGATGC | ACAAACCCCTCTACCCACCTAAATC | 274                   |
| p16\( ^{R/K} \)(M) | GAGGGTGGGGCGGATCG | GACCCGAACCGCCGACG | 143                   |
| p16\( ^{R/K} \)(U) | TTATGAGGGGGGTGGTTGGATTTG | CAACCCCAAACCACAACTAAAT | 145                   |
| RASSF1A (M)   | GAGGGGAAAAGGAAGGTTAAGG | CAATCTAATAACCTCAAACCTC | 260                   |
| RASSF1A (M)   | GGGGGTTTTCGAGAGGAGCC | CCCGATTAACCCCGTACCTCG | 203                   |
| RASSF1A (U)   | GTTTTTTGAGGAGGTTTTTTT | ACACTAACAACACACCACAAAC | 172                   |
| TIMP3 (M)     | GCATCGGAAGGTTAAGGTTTG | CTCTCCAAATTACCGTACCG | 116                   |
| TIMP3 (U)     | TGTCCTGCAAGGTTAAGGTTTG | ACTCTCCAAATTACCGTACCG | 122                   |
| PCQAP 5' (M)  | GATTTGGTATTAGGAGGAGGCGCC | AAAATCCCAATACCCAAAACC | 167                   |
| PCQAP 5' (U)  | GATTTGGTATTAGGAGGAGGCGCC | AAAATCCCAATACCCAAAACC | 167                   |

MI: methylation-independent primers; M: methylation primers; U: unmethylation primers.

2.6. DNA Bisulfite Conversion

EpiTect Plus DNA Bisulfite Kit (QIAGEN, Hilden, Germany; cat No.: 59124) was used for DNA bisulfite conversion according to the manufacturer’s instructions. The bisulfite reaction mix was prepared at room temperature using 20 \( \mu \)L (1 \( \mu \)g/\( \mu \)L) of thawed DNA. Bisulfite-converted DNA
(50 ng/µL) in elution buffer was immediately used for the MS-PCR or stored at −20 °C. DNA purity and the concentrations were assessed using a NanoDrop™-1000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA).

2.7. Target Gene Selection

A panel of four genes with tumor-suppressor activities was selected to examine methylation abnormalities in promoter regions. These TSGs were described as targets for epigenetic silencing in diverse human cancers. Among these, p16INK4a is involved in cell-cycle control, RASSF1A in apoptosis, TIMP3 in cell invasion, and PCQAP/MED15 in transcription regulation [10,12,13,26]. These TSGs were already evaluated in other studies, and our plan was to validate them in a different geographical population [22,26,38]. Initially, p16 promoter hypermethylation was discovered to be involved in the pathogenesis of oral pre-cancerous lesions associated with betel quid chewing in Sri Lanka [15]. Two previous studies reported that RASSF1A, p16, and PCQAP/MED15 TSG salivary methylation markers are useful in detecting hypermethylation events in HNSCC patients [11,26]. Similarly, Lim et al. in 2016 showed that a p16INK4a, RASSF1A, TIMP3, and PCQAP/MED15 salivary methylation marker panel offers the potential in detecting early-stage HPV-negative HNSCC tumors [39]. Thus, we presumed that the evaluation of promoter hypermethylation of these four selected TSGs would be collectively useful as a diagnostic tool for the early detection of OC/OPC.

2.8. Methylation Analysis of TSGs Using MS-PCR Assay

The methylation status of the selected TSGs was detected using the MS-PCR assay for bisulfite-converted DNA [29]. Specificity of each MS-PCR primer pair used in the current study (Table 1) was validated by previous studies [10,11,26,31,39]. Both methylation and unmethylation primer pairs were tested using bisulfite-unconverted DNA to determine their specificity and they were found not to amplify. Unmethylation PCR was used as a normalizer for the methylation PCR. Any sample which showed no unmethylation band was either discarded from the analysis or the PCR was repeated. For each set of MS-PCR, a tumor sample with known hypermethylation was used as a positive control, while DNase/RNase-free distilled water was used for the negative PCR control.

We used a previously reported nested MS-PCR method to detect the promoter CpG methylation of p16INK4a and RASSF1ATSGs [26]. Methylation-independent primers of p16INK4a and RASSF1A TSGs were used at 0.5 µM in a standard PCR (25 µL of reaction volume) using Go Taq DNA polymerase (Promega, Madison, WI, USA) with 3 µL (150 ng) of bisulfite-converted DNA template (diluted either three- or five-fold depending on the DNA concentration) and supplied 1× Go Taq Flexi Buffer, 2.5 mM MgCl2, and 0.6 mM dNTPs (Promega-USA). The following cycling conditions were applied for the stage-1 PCR: initial denaturation at 94 °C for 5 min, 35 cycles of denaturation at 94 °C for 30 s, primer annealing at 60 °C for 30 s, primer extension at 72 °C for 30 s, and a final extension at 72 °C for 5 min. To detect unmethylated or methylated alleles for p16INK4a and RASSF1A genes, stage-2 unmethylation and methylation touchdown gradient PCR was carried out using 1 µL from the stage-1 product as the DNA template. Both touchdown gradient PCRs involved an initial denaturation at 94 °C for 5 min, 25 cycles of denaturation at 94 °C for 30 s, primer annealing with temperature decreasing from 64 °C to 56 °C in 2 °C/5-cycle steps, primer extension at 72 °C for 30 s, and a final extension at 72 °C for 5 min.

For both TIMP3 and PCQAP/MED15 TSGs, specific methylation and unmethylation primer sets (1 µM) were used in two separate PCR reactions in a standard PCR. For both methylation and unmethylation reactions, a ratio of 25:1 of the total bisulfite-converted DNA template was taken. Methylation and unmethylation PCRs of the TIMP3 gene consisted of an initial denaturing stage at 95 °C for 5 min, followed by 40 cycles of 30 s at 94 °C, 30 s at 54 °C, and 30 s at 72 °C, and a final extension at 72 °C for 5 min. We used methylation and unmethylation primer sets specific for the CpG islands in the main promoter region of PCQAP/MED15 gene (PCQAP5'). For PCQAP5', both methylation and unmethylation PCRs involved an initial denaturing stage at 95 °C for 5 min, followed by 35 cycles of 30 s at 94 °C, 30 s at 62.5 °C, and 1 min at 72 °C, and a final extension at 72 °C for 5 min.
2.9. Agarose Gel Electrophoresis and Determination of Gene Methylation Levels

A volume of 5 µL of each PCR amplicon was visualized on 4% agarose gels. Samples that gave strong consistent bands were exclusively used for the promoter methylation analysis. PCR Fusion SL gel documentation system (VilberLourmat, Marne la Vallee, France) was used to scan gels, and band intensities of each sample were determined using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Finally, the ratio between methylated and unmethylated band intensities was calculated using Microsoft Excel (Microsoft Corporation, Redmond, Washington, DC, USA). Quantification of band intensities was carried out by two independent researchers to minimize observational errors.

2.10. Statistical Analysis

Statistical analysis was performed using SPSS version 20 for Windows (IBM-SPSSStatistics, IBM Corporation, Armonk, NY, USA) and Graph-Pad Prism (GraphPad Software, Inc., San Diego, CA, USA) software packages. Comparisons of normally distributed variables of independent samples were performed using the t-test. Since methylation levels were not normally distributed, non-parametric Mann–Whitney U test was used to compare methylation levels of normal healthy controls with those of OC and OPC patients. Chi-square test and binary logistic regression assessed the relationship (combined effect and the independent effect, respectively) between the presence of OC/OPC and predictor variables/risk factors. Calculated odds ratios (OR) measured the risk of developing OC and OPC. Wald statistic was used to determine parameter significance (p-value) in logistic regression models. All statistical tests were two-tailed, and significant differences between two categorical variables were marked with * p < 0.05, ** p < 0.001, and *** p < 0.0001.

CombiROC web tool (http://CombiROC.eu) was used to determine the clinical performance of these four methylation markers in discriminating OC and OPC subjects from healthy controls [40]. Optimal marker combinations and their clinical performance were determined through the combinatorial analysis of the receiver operating characteristic (ROC) curves provided by the CombiROC tool. The 10-fold cross-validation (CV) step was used to attain a reliable estimation of the clinical performance of the best marker combination [40]. This step is crucial as it could avoid the risk of over-fitting and show how well the panel translates into clinical diagnosis. Analyzing the statistical significance of the area under the curve (AUC) value is imperative, as the CV procedure could generate over-optimistic results. Therefore, permutation tests were performed to assess the statistical significance of AUC values generated by each ROC curve analysis.

3. Results

3.1. Population Characteristics of the Study Cohorts

Both patient cohorts and controls were found comparable in age and gender. Mean age of OC and OPC subjects and of normal healthy subjects was 62 ± 12.5, 62 ± 10.1, and 60 ± 7.1 years, respectively. A male preponderance was evident in both OC (90.7%) and OPC (94.1%) cohorts (Table 2). A majority of the OC (79.7%) and OPC (91.2%) patients were smokers, where most of them consumed more than five cigarettes daily (Table 2). Higher levels of alcohol consumption (OC = 74.1%; OPC = 91.2%) and betel quid chewing (OC = 77.8%; OPC = 76.4%) were recorded in patient cohorts, where a majority of them were habitual consumers for more than 25 years of their lifespan (Table 2).
Table 2. Socio-demographic and tumor characteristics of the study cohorts.

| Demographic characteristics | OC (N = 54) | OPC (N = 34) | Healthy Controls (N = 60) |
|-----------------------------|-------------|-------------|-------------------------|
| **Mean age**                |             |             |                         |
| <50                         | 7 (13.0)    | 3 (8.8)     | 1 (1.6)                 |
| 50–59                       | 11 (20.3)   | 13 (38.2)   | 29 (48.3)               |
| >60                         | 36 (66.7)   | 18 (53.0)   | 30 (50)                 |
| **Gender**                  |             |             |                         |
| Male                        | 49 (90.7)   | 32 (94.1)   | 55 (91.6)               |
| Female                      | 5 (9.3)     | 2 (5.9)     | 5 (8.4)                 |
| **Smoking**                 |             |             |                         |
| Cigarettes/day smoked       |             |             |                         |
| Non-smokers                 | 11 (20.3)   | 3 (8.8)     | 39 (65.0)               |
| 1 to 5                      | 14 (26.0)   | 11 (32.4)   | 8 (13.3)                |
| >5                          | 29 (53.7)   | 20 (58.8)   | 13 (21.6)               |
| **Alcohol use**             |             |             |                         |
| Number of years in use      |             |             |                         |
| Non-drinkers                | 14 (25.9)   | 3 (8.8)     | 31 (51.6)               |
| 1–25                        | 14 (25.9)   | 12 (35.3)   | 10 (16.6)               |
| >25                         | 26 (48.2)   | 19 (55.9)   | 19 (31.6)               |
| **Betel quid chewing**      |             |             |                         |
| Number of years in use      |             |             |                         |
| Non-consumers               | 12 (22.2)   | 8 (23.5)    | 41 (68.3)               |
| 1–25                        | 16 (29.6)   | 9 (26.5)    | 7 (11.6)                |
| >25                         | 26 (48.2)   | 17 (50.0)   | 12 (20)                 |
| **HPV infection**           |             |             |                         |
| HPV Positive                | 5 (9.2)     | 3 (8.8)     | 1 (1.6)                 |
| HPV Negative                | 49 (90.8)   | 31 (91.2)   | 59 (98.4)               |
| **Tumor characteristics**   |             |             |                         |
| **Anatomic site**           |             |             |                         |
| Lips                        | 2 (3.7)     |             |                         |
| Tongue (Front 2/3)          | 26 (48.1)   |             |                         |
| Hard palate                 | 1 (1.9)     |             |                         |
| Buccal mucosa               | 21 (38.9)   |             |                         |
| Mouth floor                 | 3 (5.5)     |             |                         |
| Retromolar                  | 1 (1.9)     |             |                         |
| Tongue (Back 1/3)           |             | 0 (0)       |                         |
| Soft palate                 |             | 7 (20.6)    |                         |
| Tonsillar pillar            |             | 12 (35.3)   |                         |
| Back wall of the throat     |             | 15 (44.1)   |                         |
| **Tumor grade**             |             |             |                         |
| Well differentiated (1)      | 24 (44.4)   | 17 (50.0)   |                         |
| Moderately differentiated (2)| 7 (13.0)   | 5 (14.8)    |                         |
| Poorly differentiated (3)   | 0 (0)       | 2 (5.9)     |                         |
| Undifferentiated (4)        | 19 (35.2)   | 6 (17.6)    |                         |
| Unknown                     | 4 (7.4)     | 4 (11.7)    |                         |
| **Tumor stage**             |             |             |                         |
| Early stage (I, II)         | 8 (14.8)    | 2 (5.9)     |                         |
| Advanced stage (III, IV)    | 23 (42.6)   | 13 (38.2)   |                         |
| Unknown                     | 23 (42.6)   | 19 (55.9)   |                         |

OC: oral cancer; OPC: oropharyngeal cancer; HPV: human papillomavirus. N: Total number of subjects in each cohort.

Regarding the primary tumor site of cancer patients, most of the OC cases were cancers on the front two-thirds of the tongue (48.1%), while cancers on the back wall of the throat were common in OPC.
cases (44.1%). In addition, grade 1 (well differentiated) tumors were common among cancer patients (OC = 44.4%; OPC = 50.0%) compared to other tumor grades. Although cancer tumor/node/metastasis (TNM) stage information was unavailable for all patients, the majority of the recruited patients (OC = 42.6%; OPC = 38.2%) were in advanced stages of cancer development (Table 2).

3.2. HPV-L1 Analysis

Detecting the presence of the HPV-L1 in salivary DNA samples provides an accurate output on high-risk HPV strains [36]. In this study, the HPV-L1 was detected in five OC subjects, three OPC subjects, and a single subject from the normal healthy control cohort (Figure 1).

3.3. Combined and Independent Effect Assessment of Etiologic Agents of OC and OPC

Combined and independent effects of the risk factors of OC and OPC are summarized in Table 3. Examination of the effects of established risk factors on OC and OPC revealed that smoking, alcohol use, and betel quid chewing had significant combined effects for both cancer types. Smoking demonstrated the strongest combined effect for OC (OR = 7.3 (95% confidence interval (CI) = 2.8–18.6)), as well as for OPC (OR = 19.2 (95% CI = 4.7–89.8)). In addition, a substantial independent effect was also noted to be driven by smoking for both OC (OR = 7.8 (95% CI = 2.1–28.4)) and OPC (OR = 20.8 (95% CI = 2.4–178.2)). Although the combined effect of HPV infection was not significant for both cancer types, it exerted a substantially high independent effect for OPC (OR = 19.6 (95% CI = 1.0–146.4)) compared to OC (OR = 6.7 (95% CI = 0.6–123.8)) development.

### Table 3. Combined and independent effects of established and emerging risk factors of OC and OPC.

| Cancer Type | Predictor Variable/Risk Factor | Crude OR (95% CI) | p-Value a | Adjusted OR R (95% CI) | p-Value b |
|-------------|--------------------------------|-----------------|-----------|------------------------|-----------|
| OC          | Smoking                        | 7.3 (2.8–18.6)  | <0.0001   | 7.8 (2.1–28.4)         | <0.05     |
|             | Alcohol use                    | 3.1 (1.2–7.3)   | <0.05     | 0.6 (0.1–2.0)          | 0.385     |
|             | Betel quid chewing             | 7.1 (3.0–19.2)  | <0.0001   | 5.7 (2.2–14.3)         | <0.05     |
|             | HPV infection                  | 6.0 (0.6–140.9) | 0.07      | 6.7 (6.0–123.8)        | <0.05     |
| OPC         | Smoking                        | 19.2 (4.7–89.8) | <0.0001   | 20.8 (2.4–178.2)       | <0.05     |
|             | Alcohol use                    | 11.0 (2.7–51.0) | <0.0001   | 0.8 (0.1–6.7)          | 0.854     |
|             | Betel quid chewing             | 7.0 (2.4–20.7)  | <0.0001   | 3.9 (1.2–12.4)         | <0.05     |
|             | HPV infection                  | 5.7 (0.4–148.9) | 0.133     | 19.6 (1.0–146.4)       | <0.05     |

OR: odds ratio; CI: confidence interval. Non-consuming/non-infected group was selected as the reference group for each predictor variable/risk factor. Combined effects of risk factors were assessed using crude OR values derived by chi-square test a, while independent effects were assessed using adjusted OR values derived by binary logistic regression analysis b. Adjusted OR^R^: adjusted for smoking, alcohol use, betel quid chewing, and HPV infection. Significant effect of each predictor variable is marked with * p < 0.05 or *** p < 0.0001.

**Figure 1.** Agarose gel electrophoresis of HPV-L1 analysis. L: 100-bp DNA ladder with 500-bp marker; P: positive control; N: negative PCR control. Samples 1–5: oral cancer (OC) patient samples; Samples 6–8: oropharyngeal cancer (OPC) patient samples; Sample 9: healthy control sample.
3.4. Comparative DNA Methylation Analysis of Individual TSGs

Agarose gels analyzed for the detection of promoter hypermethylation events for all four TSGs are presented in Figure 2. Salivary DNA promoter methylation levels of TSGs were comparatively analyzed among the three study cohorts (Figure 3). Accordingly, only RASSF1A, TIMP3, and PCQAP/MED15 TSGs showed significant promoter methylation (hypermethylation) in saliva collected from OC subjects ($p < 0.0001$, $p < 0.05$, and $p < 0.0001$, respectively) and from OPC subjects ($p < 0.0001$, $p < 0.001$, and $p < 0.0001$, respectively), compared to normal healthy controls. Conversely, there was no significant difference in promoter methylation levels between OC subjects and OPC subjects, for any of the four TSGs examined.

Figure 2. Agarose gel electrophoresis of methylation-specific PCR (MS-PCR) analysis of tumor-suppressor genes (TSGs). L: 100-bp DNA ladder with 500-bp marker; P: positive control; U: unmethylated amplicon; M: methylated amplicon; N: negative PCR controls (for unmethylation and methylation PCR). Samples 1–3: OC patient samples; Samples 4 and 5: OPC patient samples.
TSGs (RASSF1A p16 (Table 4). Also, betel quid chewers demonstrated significant promoter hypermethylation of all four TSGs (RASSF1A compared to low-grade OPC tumors (Table 4). A significant promoter hypermethylation was observed in advanced OC stages, compared with early/less advanced OC stages (Table 4). Further, we found that p16INK4a, TIMP3, and PCQAP/MED15 TSGs were significantly hypomethylated (p < 0.001, p < 0.001, and p < 0.001, respectively) in saliva of HPV-positive subjects compared to HPV-negative subjects (Table 4). A significant p16INK4a and RASSF1A promoter hypermethylation (p < 0.001 and p < 0.05, respectively) was observed in advanced OC stages, compared with early/less advanced OC stages (Table 4). In addition, substantial promoter hypermethylation was noted between p16INK4a and RASSF1A TSGs (p < 0.05 and p < 0.05, respectively) in high-grade (grades 3 and 4) OC tumors compared to low-grade (grades 1 and 2) OC tumors. For OPC, p16INK4a, RASSF1A, and TIMP3 TSGs were significantly hypermethylated (p < 0.05, p < 0.05, and p < 0.05, respectively) in high-grade OPC tumors compared to low-grade OPC tumors (Table 4).
Table 4. Association of promoter hypermethylation of tumor-suppressor genes (TSGs) with demographic factors, risk factors, and clinicopathological characteristics.

| Variable          | Category            | N  | p16^{INK4a} Meth | p-Value * | RASSF1A Meth | p-Value * | TIMP3 Meth | p-Value * | PCQAP/MED15 Meth | p-Value * |
|-------------------|---------------------|----|-----------------|-----------|--------------|-----------|------------|-----------|-----------------|-----------|
| Age               | ≥62 a               | 28 | 13              | 0.455     | 12           | 0.244     | 18         | 0.414     | 21              | 0.550     |
|                   | <62 a               | 60 | 58              |           | 54           |           | 52         |           | 52              |           |
| Gender            | Male                | 80 | 63              | 0.053     | 61           | 0.133     | 69         | 0.152     | 66              | 0.164     |
|                   | Female              | 8  | 5               |           | 4            |           | 5          |           | 5               |           |
| Smoking           | Consumers           | 74 | 57              | <0.05 *   | 58           | <0.05 *   | 61         | 0.199     | 62              | 0.240     |
|                   | Non-consumers       | 14 | 11              |           | 7            |           | 13         |           | 9               |           |
| Alcohol use       | Consumers           | 71 | 56              | <0.05 *   | 56           | <0.05 *   | 61         | 0.665     | 60              | 0.060     |
|                   | Non-consumers       | 17 | 12              |           | 9            |           | 13         |           | 11              |           |
| Betel quid Chewing| Consumers           | 68 | 51              | <0.05 *   | 52           | <0.05 *   | 61         | <0.001 ** | 57              | <0.05 *   |
|                   | Non-consumers       | 20 | 17              |           | 13           |           | 13         |           | 14              |           |
| HPV-L1            | HPV-positive        | 8  | 6               | <0.001 ** | 6            | 0.061     | 8          | <0.001 ** | 7               | <0.001 ** |
|                   | HPV-negative        | 80 | 62              |           | 54           |           | 66         |           | 64              |           |
| Tumor grade       | OC Grade 3, 4       | 19 | 13              | <0.05 *   | 13           | <0.05 *   | 15         | 0.311     | 16              | 0.289     |
|                   | Grade 1, 2          | 31 | 25              |           | 24           |           | 28         |           | 27              |           |
|                   | OPC Grade 3, 4      | 8  | 7               | <0.05 *   | 5            |           | 4          | <0.05 *   | 2               | 0.146     |
|                   | Grade 1, 2          | 22 | 17              |           | 17           |           | 21         |           | 21              |           |
| Tumor stage       | OC Stage (III, IV)  | 23 | 18              | <0.001 ** | 17           | <0.05 *   | 17         | 0.233     | 19              | 0.712     |
|                   | Stage (I, II)       | 8  | 7               |           | 6            |           | 7          |           | 6               |           |
|                   | OPC Stage (III, IV) | 13 | 8               | 0.525     | 10           | 0.930     | 10         | 0.076     | 11              | 0.964     |
|                   | Stage (I, II)       | 2  | 2               |           | 2            |           | 2          |           | 1               |           |

a Mean age; b Mann–Whitney U test; N: total number of patients in each category; Meth: number of patients with methylated gene promoter regions. A significant difference in the promoter methylation level between two categories is indicated as * p < 0.05 or ** p < 0.001.
3.6. Performance of the Methylation Marker Panel in Discriminating OC and OPC from Healthy Controls

The CombiROC curve analysis identified the best performing marker combination by evaluating its clinical performance in discriminating OC, OPC, and healthy control cohorts (Table 5). Intriguingly, the marker combination of all four markers (quadruple-methylation marker panel) performed well in discriminating OC patients from healthy controls with an AUC of 0.92 and accuracy (ACC) of 0.92, with a sensitivity of 91.7% and 92.3% specificity (Table 5; Figure 4a). Furthermore, this marker panel performed exceptionally well with an AUC of 0.97 and ACC of 0.96, with a sensitivity of 99.8% and 92.1% specificity when discriminating OPC patients from healthy controls (Table 5; Figure 4b). Next, the performance of the quadruple-methylation marker panel was investigated using a 10-fold CV and permutation test, aiming for the effective clinical validation of the marker panel. Results of the CV procedure suggest that the quadruple-methylation marker panel is a perfect fit for the diagnosis of OC and OPC patients from healthy controls, as the overall accuracy, sensitivity, and specificity were least affected by the imposed likelihood (Table 5; Figure 4a,b). In addition, we obtained the “real AUC value” outside the permuted AUC distribution, which signified the high validity of this marker panel in discriminating OC and OPC subjects from normal healthy controls (Figure 4c,d).

![Figure 4](image-url)

**Figure 4.** Performance of the quadruple-methylation marker panel. CombiROC curve analysis of the marker panel in discriminating (a) OC patients and (b) OPC patients from normal healthy controls. Green bar: receiver operating characteristic (ROC) curve of the marker panel for the whole cohort. Gray dotted bar: 10-fold cross-validation (CV) test of the marker panel. Diagonal line: reference line with zero discriminating power (0.5 sensitivity and specificity). Density distribution of permuted area under the curve (AUC) values compared to the normal distribution, illustrating the significance of real AUC value generated for discriminating (c) OC subjects and (d) OPC subjects from healthy controls.
Table 5. CombiROC curve analyses and validation tests of the quadruple-methylation marker panel.

|                          | AUC | ACC | Error Rate (1-ACC) | SE% | SP% | PPV% | NPV% |
|--------------------------|-----|-----|--------------------|-----|-----|------|------|
| (a) Performance in discriminating OC from healthy controls |     |     |                    |     |     |      |      |
| Whole cohort             | 0.92| 0.92| 0.08               | 91.7| 92.3| 95.7 | 85.7 |
| 10-fold CV               | 0.85| 0.87| 0.14               | 83.3| 92.3|      |      |
| Permutated models        | 0.71| 0.71| 0.29               | 69.7| 76.0|      |      |
| (b) Performance in discriminating OPC from healthy controls |     |     |                    |     |     |      |      |
| Whole cohort             | 0.97| 0.96| 0.04               | 99.8| 92.1| 93.7 | 98.6 |
| 10-fold CV               | 0.82| 0.89| 0.11               | 86.7| 92.3|      |      |
| Permutated models        | 0.60| 0.66| 0.33               | 65.1| 68.7|      |      |
| (c) Performance in discriminating OC from OPC |     |     |                    |     |     |      |      |
| Whole cohort             | 0.65| 0.72| 0.28               | 91.7| 40.0| 61.2 | 53.3 |
| 10-fold CV               | 0.60| 0.56| 0.44               | 33.3| 93.3|      |      |
| Permutated models        | 0.70| 0.70| 0.30               | 68.8| 73.9|      |      |

Clinical performance of the quadruple-methylation marker panel in discriminating (a) OC from healthy controls, (b) OPC from healthy controls, and (c) OC from OPC was determined with respect to all key parameters. AUC: area under the curve; ACC: accuracy; SE: sensitivity; SP: specificity; PPV: positive predictive value; NPV: negative predictive value.

4. Discussion

This study evaluated cohorts of OC and OPC patients and matched healthy controls to determine the utility of the MS-PCR approach combined with a densitometry analysis to assess promoter methylation levels of $p16^{INK4a}$, RASSF1A, TIMP3, and PCQAP/MED15 TSGs in saliva-derived DNA. Conforming to the high diagnostic accuracy detected, the strong potential of this quadruple-methylation marker panel in discriminating OC and OPC patients from healthy controls was clearly evident.

TSGs analyzed in our study were found to be associated with common oncogenic transformation pathways and cellular functions that are frequently dysregulated in many cancers including OC and OPC. The $p16^{INK4a}$ gene encodes for a cyclin-dependent kinase 4 (CDK 4) inhibitor which regulates the retinoblastoma (Rb) pathway and arrests the cell cycle [41]. Hence, its inactivation may lead to disruption of cell cycle control ultimately inducing tumorigenesis in various cancers including OC [42–46]. However, no significant $p16^{INK4a}$ promoter methylation was observed in both OC and OPC salivary rinses, although this gene was reported to be highly methylated in previous HNSCC studies [15,26,44,47,48]. A recent study of OSCC patients in a south Indian population reported significant $p16$ promoter hypermethylation (38%) [49]. This contradiction of detecting different methylation frequencies can be explained by the differences in sampling methods, the sensitivity of the detection method, location and length of investigated CpG repeats, and cohort composition.

Ras association domain family 1 isoform A (RASSF1A) acts as a downstream negative effector of the Ras protein which induces growth arrest of cells (apoptosis) [50]. Recent evidence suggests that RASSF1A expression is dependent on angiogenic signaling events during cancer progression [51]. It is well documented that the RASSF1A TSG is frequently inactivated in primary oral tumors by de novo methylation of promoter CpG islands, subsequently triggering OC initiation [26,39,52]. Significant RASSF1A promoter hypermethylation detected by our study in both OC and OPC salivary rinses suggests its strong association with OC and OPC risk.

Tissue inhibitor of metalloproteinases (TIMPs) is known as an inhibitor of cellular invasion, metastasis and angiogenesis [53]. Loss of TIMP expression by TIMP3 TSG promoter hypermethylation is speculated specifically with HNSCC neoplastic evolution [38,54]. Our study reiterates previous reports that evidence the positive correlation between TIMP3 promoter hypermethylation in oral malignancies [12,38,55,56].
Similarly, we observed a substantial PCQAP/MED15 hypermethylation in both OC and OPC, which is in line with previous studies on HNSCC [11,39]. Although PCQAP/MED15 methylation in HNSCC was identified and validated recently, it is frequently implicated in prostate and endometrial cancer etiologies [11,42]. The PC2 glutamine/Q-rich-associated protein (PCQAP) is identified as a transcriptional co-activator mediator, responsible for the transcriptional regulation of ligand-activated proteins which plays a pivotal role in cellular regulation, proliferation, and differentiation [11,57].

Age- and sex-specific differences in promoter hypermethylation of $p16^{\text{INK4a}}$ and RASSF1A TSGs were previously reported [58]. Conversely, no direct association was observed between TSG promoter methylation with age and sex in both cancer types, in agreement with a few previous reports [39]. It is well known that $p16^{\text{INK4a}}$ and RASSF1A promoter methylation status is strongly correlated with the cancer stage [59,60]. By confirming these findings, our study established a significant $p16^{\text{INK4a}}$ and RASSF1A promoter hypermethylation in advanced stage of OC subjects, suggesting that these alterations may occur late in the carcinogenesis of the oral cavity. Also, we found significant promoter hypermethylation in high tumor grades of OC for $p16^{\text{INK4a}}$, RASSF1A, and TIMP3, suggesting the correlation between promoter hypermethylation of tumor-related genes and poor prognosis of OC and OPC [26,61,62].

Our results strengthened the notion that smoking and alcohol consumption are strong predictors of $p16^{\text{INK4a}}$ and RASSF1A promoter hypermethylation [63–65]. Carcinogens in tobacco smoke could drive genetic and epigenetic mutations in frequently exposed tissues [66]. Tobacco smoking also induces DNA methyltransferase (DNMT) activity, thereby causing de novo methylation on disposed loci on a gene-specific basis [67,68]. Significant promoter hypermethylation observed in OPC subjects compared to OC subjects may be attributed to the higher independent risk of smoking observed in OPC subjects. In addition, it is well established that betel nut, as well as betel quid, with or without tobacco, is carcinogenic to HNSCC [69,70]. Betel quid chewing is critically associated with high-risk pre-cancerous oral lesions [15,71]. Furthermore, recent studies report that silencing of RASSF1A and $p16^{\text{INK4a}}$ gene expression by promoter hypermethylation may play a critical role in betel-associated oral carcinogenesis [15,72]. In agreement with prior findings, we describe a strong association between betel quid chewing and promoter hypermethylation of all four TSGs studied.

HPV is recognized as an additional independent risk factor for the development of OSCC, particularly OPSCC, confirmed by our risk analysis [73–75]. In addition, we report that $p16^{\text{INK4a}}$, TIMP3 and PCQAP/MED15 promoter regions were hypomethylated in HPV-positive cases compared to HPV-negative cases. This result seems to be paradoxical since HPV infection appears to have a greater association with promoter hypermethylation of TSGs, due to the over-expression and increased DNMT activities induced by HPV oncoproteins (E7) [76–78]. This contradiction may be caused by differences in sampling methods, ethnic origin of the subjects, and by the HPV genotype.

It follows that lifestyle factors contribute to tumorigenesis through revocable epigenetic dysregulations, thus holding great promise in disease prevention and treatment [79]. In addition, methylation profiles of TSGs in combination with clinico-pathological characters would be useful in predicting the behavior of OC and OPC. The significance of the association between clinico-pathological characteristics and promoter methylation of TSGs evaluated by the current study led us to hypothesize the degree of effect of risk factors that may have affected the performance of the quadruple-methylation marker panel. For instance, the higher AUC and sensitivity in detecting OPC patients compared to OC patients may be attributed to the substantial effect of risk factors on the development of OPC compared to OC.

Early detection of cancer, at a stage where it is localized and treatable, will substantially reduce mortality owing to the disease. For this reason, diagnostic tumor biomarkers are now an imperative field pursued in biomedical engineering [80]. It is now well established that individual biomarkers may not be sufficiently accurate in diagnosing tumors, as heterogeneity of individual tumors is triggered by specific molecular alternations in different tumor-related genes [81]. Therefore, combined biomarker panels are developed to attain significant specificity and sensitivity values for effective translation into
diagnostic settings [22,54]. Our results suggest that p16\textsuperscript{INK4a} methylation alone should not be considered as a tumor marker for OC or OPC, since no significant methylation was found in normal and tumor samples. However, hypermethylation of p16 was found to be a promising diagnostic and prognostic biomarker for recurrence-free survival of OC and OPC [82–84]. Hence, CombiROC analysis allowed us to develop a better performing combination of independent methylation markers, by lowering the risk of missing p16 marker. We defined the high performance of this quadruple-methylation marker panel which outperformed the previous individual markers and other marker combinations substantiated by previous studies in different ethnic groups [26,39,54,81,85]. We further strengthened our study by analyzing the performance, robustness, and consistency of the marker panel, through cross-validation and permutation tests, as such features of this panel would be decidedly useful as a robust diagnostic and screening tool.

The high performance of this marker panel prompts one to study its prognostic potential which could be useful during disease surveillance following treatment or with high-risk cohorts, such as smokers and alcohol users. Notably, evaluating the accuracy of genetic screening tests for oral HPV infections is a promising area of research. However, a genetic screening method for oral HPV infections is yet to be approved by the Food and Drug Administration (FDA); hence, it is rarely practiced in developing countries. A previous study reported the high accuracy of a methylation marker panel in discriminating HPV-positive HNSCC cases from HPV-negative counterparts [39]. Given the low prevalence of HPV-positive OC/OPC cases in our study, the current marker panel was not assessed for its performance in discriminating HPV-positive cancer cases from their HPV-negative counterparts. The low prevalence of HPV in our analysis (9.1%) is probably explained by the abundance of squamous cell carcinomas of the oral cavity (61.4%) among our samples, in agreement with previous reports [86,87].

Since its introduction, the MS-PCR method progressively gained favor as a preferred tool for detecting the DNA methylation status of CpG islands. Nevertheless, some studies showed that it was prone to overestimate methylation prevalence, leading to a high number of false positives (i.e., low specificity) due to incomplete bisulfite conversion [88,89]. Also, it cannot distinguish the methylation status between normal epithelium and tumor cells. This explains the different methylation levels observed in the current study compared to available literature. A previous study, validating TSG methylation markers for diagnosing OSCC, showed that quantitative methylation-specific PCR analyses (Q-MSP) may be a better choice in improving the level of detection. Alternatively, pyrosequencing technology emerged as a robust and versatile platform in global DNA methylation quantification, which may overcome the limitations of MSP-based methods [90,91]. Several studies evaluated both the accuracy and precision of pyrosequencing for the analysis of DNA methylation in heterogeneous mixtures of tumor DNA samples [92,93].

Our work clearly emphasizes the need for assessing other promising genes in saliva to improve the sensitivity and specificity of this current marker panel. The optimized marker panel will finally be evaluated for performance in prospective trials to depict its clinical efficacy. Validation of this panel is expected to involve screening of high-risk populations followed by clinical assessment using biopsy tests for individuals whose methylation profile expresses the highest risk for OC or OPC. Our findings highlight the potential of this marker panel comprising epigenetically silenced TSGs in saliva, which can be used for the earliest possible identification of OC/OPC incidence, permitting careful monitoring to guide immediate intervention and further evaluation.

5. Conclusions

We report that frequent exposure to established risk factors such as smoking, alcohol use, and betel quid chewing may drive oral and oropharyngeal carcinogenesis through promoter hypermethylation of TSGs. Essentially, we established the exceptional diagnostic accuracy of the methylation marker panel consisting of p16\textsuperscript{INK4a}, RASSF1A, TIMP3, and PCQAP/MED15 TSGs in the early diagnosis of OC and OPC.
**Author Contributions:** Conceptualization, C.L., S.M., C.P. and P.U.; formal analysis, C.L. and P.U.; funding acquisition, P.U.; investigation, C.L.; methodology, C.L., A.W., K.P. and C.P.; project administration, P.U.; resources, A.W. and P.U.; supervision, P.U.; validation, C.F.; writing—original draft, C.L.; writing—review and editing, K.P., C.P. and P.U.

**Funding:** This research was funded by the University of Colombo, Sri Lanka (AP/3/2/2015/SG/29).

**Acknowledgments:** Relevant medical, nursing, and other staff members of the National Cancer Institute, Sri Lanka are acknowledged for their support in collecting samples and providing related medical information of patients.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Scully, C.; Bedi, R. Ethnicity and oral cancer. *Lancet Oncol.* 2000, 1, 37–42. [CrossRef]

2. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. *CA Cancer J. Clin.* 2015, 65, 87–108. [CrossRef]

3. Krishna Rao, S.V.; Mejia, G.; Roberts-Thomson, K.; Logan, R. Epidemiology of oral cancer in Asia in the past decade—An update (2000–2012). *Asian Pac. J. Cancer Prev.* 2013, 14, 5567–5577.

4. Siriwardena, B.S.; Tilakaratne, A.; Amaratunga, E.A.; Tilakaratne, W.M. Demographic, aetiological and survival differences of oral squamous cell carcinoma in the young and the old in Sri Lanka. *Oral Oncol.* 2006, 42, 831–836. [CrossRef] [PubMed]

5. Somatunga, L.C.; Sinha, D.N.; Sumanasekera, P.; Galapatti, K.; Rinchin, S.; Kahandaliyanage, A.; Mehta, F.R.; Nishirani Lanka, J.D. Smokeless tobacco use in Sri Lanka. *Indian J. Cancer* 2012, 49, 357–363. [CrossRef] [PubMed]

6. Warnakulasuriya, S. Global epidemiology of oral and oropharyngeal cancer. *Oral Oncol.* 2009, 45, 309–316. [CrossRef]

7. Marur, S.; D’Souza, G.; Westra, W.H.; Forastiere, A.A. HPV-associated head and neck cancer: A virus-related cancer epidemic. *Lancet Oncol.* 2010, 11, 781–789. [CrossRef]

8. Fong, Z.; Xu, Q.; Chen, W. Epigenetic and genetic alterations-based molecular classification of head and neck cancer. *Expert Rev. Mol. Diagn.* 2012, 12, 279–290. [CrossRef] [PubMed]

9. Herman, J.G. Hypermethylation of tumor suppressor genes in cancer. *Semin. Cancer Biol.* 1999, 9, 359–367. [CrossRef]

10. Righini, C.A.; de Fraipont, F.; Timsit, J.F.; Faure, C.; Brambilla, E.; Reyt, E.; Favrot, M.C. Tumor-specific methylation in saliva: A promising biomarker for early detection of head and neck cancer recurrence. *Clin. Cancer Res.* 2007, 13, 1179–1185. [CrossRef] [PubMed]

11. Ovcinnikov, D.A.; Wan, Y.; Coman, W.B.; Pandit, P.; Cooper-White, J.J.; Herman, J.G.; Punyadeera, C. DNA Methylation at the Novel CpG Sites in the Promoter of MED15/PCQAP Gene as a Biomarker for Head and Neck Cancers. *Biomark. Insights* 2014, 9, 53–60. [CrossRef]

12. Sun, W.; Zaboli, D.; Wang, H.; Liu, Y.; Arnaoutakis, D.; Khan, T.; Khan, Z.; Koch, W.M.; Califano, J.A. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer. *Clin. Cancer Res.* 2012, 18, 1082–1091. [CrossRef]

13. Supic, G.; Kozomara, R.; Brankovic-Magic, M.; Jovic, N.; Magic, Z. Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. *Oral Oncol.* 2014, 45, 1051–1057. [CrossRef]

14. Chang, H.W.; Ling, G.S.; Wei, W.I.; Yuen, A.P. Smoking and drinking can induce p15 methylation in the upper aerodigestive tract of healthy individuals and patients with head and neck squamous cell carcinoma. *Cancer* 2004, 101, 125–132. [CrossRef] [PubMed]

15. Takeshima, M.; Saitho, M.; Kusano, K.; Nagayasu, H.; Kurashige, Y.; Malsantha, M.; Arakawa, T.; Takuma, T.; Chiba, I.; Kaku, T.; et al. High frequency of hypermethylation of p14, p15 and p16 in oral pre-cancerous lesions associated with betel-quid chewing in Sri Lanka. *J. Oral Pathol. Med.* 2008, 37, 475–479. [CrossRef] [PubMed]

16. Marsit, C.J.; McClean, M.D.; Furniss, C.S.; Kelsey, K.T. Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. *Int. J. Cancer* 2006, 119, 1761–1766. [CrossRef] [PubMed]

17. Esteller, M.; Corn, P.G.; Baylin, S.B.; Herman, J.G. A gene hypermethylation profile of human cancer. *Cancer Res.* 2001, 61, 3225–3229.
18. Sidransky, D.; Irizarry, R.; Califano, J.A.; Li, X.; Ren, H.; Benoit, N.; Mao, L. Serum protein MALDI profiling to distinguish upper aerodigestive tract cancer patients from control subjects. *J. Natl. Cancer Inst.* 2003, 95, 1711–1717. [CrossRef]

19. Ahrendt, S.A.; Chow, J.T.; Xu, L.H.; Yang, S.C.; Eisenberger, C.E.; Esteller, M.; Herman, J.G.; Wu, L.; Decker, P.A.; Jen, J.; et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. *J. Natl. Cancer Inst.* 1999, 91, 332–339. [CrossRef]

20. Cairns, P.; Esteller, M.; Herman, J.G.; Schoenberg, M.; Jeronimo, C.; Sanchez-Cespedes, M.; Chow, N.H.; Grasso, M.; Wu, L.; Westra, W.B.; et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. *Clin. Cancer Res.* 2001, 7, 2727–2730. [PubMed]

21. Evron, E.; Dooley, W.C.; Umbricht, C.B.; Rosenthal, D.; Sacchi, N.; Gabrielson, E.; Soito, A.B.; Hung, D.T.; Ljung, B.; Davidson, N.E.; et al. Detection of breast cancer cells in ductal lavage fluid by methylationspecific PCR. *Lancet* 2001, 357, 1335–1336. [CrossRef]

22. Carvalho, A.L.; Jeronimo, C.; Kim, M.M.; Henrique, R.; Zhang, Z.; Hoque, M.O.; Chang, S.; Braut, M.; Nayak, C.S.; Jiang, W.W.; et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. *Clin. Cancer Res.* 2008, 14, 97–107. [CrossRef] [PubMed]

23. Hu, S.; Arellano, M.; Boontheung, P.; Wang, J.; Zhou, H.; Jiang, J.; Elashoff, D.; Wei, R.; Loo, J.A.; Wong, D.T. Salivary proteomics for oral cancer biomarker discovery. *Clin. Cancer Res.* 2008, 14, 6246–6252. [CrossRef]

24. Ogata, S.; Hamada, T.; Yamada, N.; Yokoyama, S.; Kitamoto, S.; Kanmura, Y.; Nomura, M.; Kamikawa, Y.; Yonezawa, S.; Sugihara, K. Aberrant DNA methylation of tumor-related genes in oral rinse: A noninvasive method for detection of oral squamous cell carcinoma. *Cancer* 2012, 118, 4298–4308. [CrossRef] [PubMed]

25. Pfaff, T.; Cooper-White, J.; Beyerlein, P.; Kostner, K.; Punyadeera, C. Diagnostic potential of saliva: Current state and future applications. *Clin. Chem. 2011*, 57, 675–687. [CrossRef]

26. Ovchinnikov, D.A.; Cooper, M.A.; Pandit, P.; Coman, W.B.; Cooper-White, J.J.; Keith, P.; Wolvetang, E.J.; Slowey, P.D.; Punyadeera, C. Tumor-suppressor Gene Promoter Hypermethylation in Saliva of Head and Neck Cancer Patients. *Transl. Oncol.* 2012, 5, 321–326. [CrossRef] [PubMed]

27. Shah, F.D.; Begum, R.; Vajaria, B.N.; Patel, K.R.; Patel, J.B.; Shukla, S.N.; Patel, P.S. A review on salivary genomics and proteomics biomarkers in oral cancer. *Indian J. Clin. Biochem.* 2011, 26, 326–334. [CrossRef] [PubMed]

28. Viet, C.T.; Schmidt, B.L. Methylation array analysis of preoperative and postoperative saliva DNA in oral cancer patients. *Cancer Epidemiol. Biomarkers Prev.* 2008, 17, 3603–3611. [CrossRef]

29. Herman, J.G.; Graff, J.R.; Myohanen, S.; Nelkin, B.D.; Baylin, S.B. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. *Proc. Natl. Acad. Sci. USA* 1996, 93, 9821–9826. [CrossRef]

30. Rand, K.; Qu, W.; Ho, T.; Clark, S.J.; Molloy, P. Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives. *Methods* 2002, 27, 114–120. [CrossRef]

31. Divine, K.K.; Liechty, K.C.; Crume, K.C.; Belinsky, S.A. Nested multigene MSP/DHPLC method for analyzing promoter hypermethylation status in clinical samples. *Biotechniques* 2006, 40, 40–48. [CrossRef] [PubMed]

32. Huang, Z.; Bassil, C.F.; Murphy, S.K. Methylation-specific PCR. *Methods Mol. Biol.* 2013, 1049, 75–82. [PubMed]

33. Topkas, E.; Keith, P.; Dimelso, G.; Cooper-White, J.; Punyadeera, C. Evaluation of saliva collection devices for the analysis of proteins. *Clin. Chim. Acta* 2012, 413, 1066–1070. [CrossRef] [PubMed]

34. Mohamed, R.; Campbell, J.L.; Cooper-White, J.; Dimelso, G.; Punyadeera, C. The impact of saliva collection and processing methods on CRP, IgE, and Myoglobin immunoassays. *Clin. Transl. Med.* 2012, 1, 19. [CrossRef] [PubMed]

35. Jain, M.; Nijhawan, A.; Tyagi, A.K.; Kurhana, J.P. Validation of housekeeping genes as internal control for studying gene expression in rice by quantitative real-time PCR. *Biochem. Biophys. Res. Commun.* 2006, 345, 646–651. [CrossRef]

36. de Roda Husman, A.M.; Walboomers, J.M.; van den Brule, A.J.; Meijer, C.J.; Snijders, P.J. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. *J. Gen. Virol.* 1995, 76, 1057–1062. [CrossRef]

37. Eads, C.A.; Lord, R.V.; Wickrasmasinghe, K.; Long, T.I.; Kurumboor, S.K.; Bernstein, L.; Peters, J.H.; DeMeester, S.R.; DeMeester, T.R.; Skinner, K.A.; et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. *Cancer Res.* 2001, 61, 3410–3418. [PubMed]
38. Rettori, M.M.; de Carvalho, A.C.; Longo, A.L.; de Oliveira, C.Z.; Kowalski, L.P.; Carvalho, A.L.; Vettore, A.L. TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors. *J. Transl. Med.* 2013, 11, 316. [CrossRef]

39. Lim, Y.; Wan, Y.; Vagenas, D.; Ovchinnikov, D.A.; Perry, C.F.; Davis, M.J.; Punyadeera, C. Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers. *BMC Cancer* 2016, 16, 749. [CrossRef]

40. Mazzara, S.; Rossi, R.L.; Griffantini, R.; Donizetti, S.; Abrignani, S.; Bombaci, M. CombiROC: An interactive web tool for selecting accurate marker combinations of omics data. *Sci. Rep.* 2017, 7, 45477. [CrossRef]

41. Gonzalez, S.; Serrano, M. A new mechanism of inactivation of the INK4/ARF locus. *Cell Cycle* 2006, 5, 1382–1384. [CrossRef]

42. Rosenbaum, E.; Hoque, M.O.; Cohen, Y.; Zahurak, M.; Eisenberger, M.A.; Epstein, J.I.; Partin, A.W.; Sidransky, D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. *Clin. Cancer Res.* 2005, 11, 8321–8325. [CrossRef] [PubMed]

43. Belinsky, S.A.; Klinge, D.M.; Dekker, J.D.; Smith, M.W.; Bocklage, T.; Gilliland, F.D.; Crowell, R.E.; Karp, D.D.; Stidley, C.A.; Picchi, M.A. Gene promoter methylation in plasma and sputum increases with lung cancer risk. *Clin. Cancer Res.* 2005, 11, 6505–6511. [CrossRef]

44. Hsu, L.S.; Lee, H.C.; Chau, G.Y.; Yin, P.H.; Chi, C.W.; Lui, W.Y. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan. *Oncol. Rep.* 2006, 15, 507–511. [CrossRef] [PubMed]

45. Ogi, K.; Toyota, M.; Ohe-Toyota, M.; Tanaka, N.; Aya, M.; Fujiwara, I.; Kubo, N.; Sawada, T.; Ohira, M.; Kato, Y.; Hirakawa, K. Frequent p16 CpG island hypermethylation in primary remnant gastric cancer suggesting an independent carcinogenic pathway. *Oncol. Rep.* 2006, 15, 615–620. [CrossRef]

46. Mino, A.; Onoda, N.; Yashiro, M.; Aya, M.; Fujiwara, I.; Kubo, N.; Sawada, T.; Ohira, M.; Kato, Y.; Hirakawa, K. Frequent p16 CpG island hypermethylation in primary remnant gastric cancer suggesting an independent carcinogenic pathway. *Oncol. Rep.* 2006, 15, 615–620. [CrossRef]

47. Kato, K.; Hara, A.; Kuno, T.; Mori, H.; Yamashita, T.; Toida, M.; Shibata, T. Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. *J. Cancer Res. Clin. Oncol.* 2006, 132, 735–743. [CrossRef] [PubMed]

48. Don, K.R.; Ramani, P.; Ramshankar, V.; Sherlin, H.J.; Premkumar, P.; Natesan, A. Promoter hypermethylation patterns of P16, DAPK and MGMT in oral squamous cell carcinoma: A systematic review and meta-analysis. *Indian J. Dent. Res.* 2014, 25, 797–805. [CrossRef] [PubMed]

49. Sushma, P.S.; Jamil, K.; Kumar, P.U.; Satyanarayana, U.; Ramakrishna, M.; Triveni, B. PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): A study on south Indian population. *Tumour Biol.* 2016, 37, 7625–7632. [CrossRef] [PubMed]

50. Spandidos, D.A.; Sourvinos, G.; Tsatsanis, C.; Zafiropoulos, A. Normal RAS genes: Their onco-suppressor and pro-apoptotic functions (review). *Int. J. Oncol.* 2002, 21, 237–241. [CrossRef]

51. Blanchard, T.G.; Lapidus, R.; Banerjee, V.; Ba; 48. Don, K.R.; Ramani, P.; Ramshankar, V.; Sherlin, H.J.; Premkumar, P.; Natesan, A. Promoter hypermethylation patterns of P16, DAPK and MGMT in oral squamous cell carcinoma: A systematic review and meta-analysis. *Indian J. Dent. Res.* 2014, 25, 797–805. [CrossRef] [PubMed]

52. Wen, G.; Wang, H.; Zhong, Z. Associations of RASSF1A, RARbeta, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis. *Medicine* 2018, 97, e9971. [CrossRef]

53. Gomez, D.E.; Alonso, D.F.; Yoshiji, H.; Thorgersson, U.P. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. *Eur. J. Cell Biol.* 1997, 74, 111–122. [PubMed]

54. Rettori, M.M.; de Carvalho, A.C.; Bomfim Longo, A.L.; de Oliveira, C.Z.; Kowalski, L.P.; Carvalho, A.L.; Vettore, A.L. Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients. *Carcinogenesis* 2013, 34, 20–27. [CrossRef]

55. Qi, J.H.; Ebrahem, Q.; Moore, N.; Murphy, G.; Claesson-Welsh, L.; Bond, M.; Baker, A.; Anand-Apte, B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): Inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. *Nat. Med.* 2003, 9, 407–415. [CrossRef] [PubMed]

56. De Schutter, H.; Geeraets, H.; Verbeken, E.; Nuysts, S. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. *Oncol. Rep.* 2009, 21, 507–513. [PubMed]

57. Sandhu, H.K.; Hollenbeck, N.; Wassink, T.H.; Philibert, R.A. An association study of PCQAP polymorphisms and schizophrenia. *Psychiatr. Genet.* 2004, 14, 169–172. [CrossRef] [PubMed]
Toyooka, S.; Maruyama, R.; Toyooka, K.O.; McLerran, D.; Feng, Z.; Fukuyama, Y.; Virmani, A.K.; Tran, T.N.; Liu, Y.; Takagi, M.; Yamaguchi, A.; Fujii, H. Frequent promoter hypermethylation of RASSF1A.

Ariyawardana, A.; Athukorala, A.D.; Arulanandam, A.E.

Vertino, P.M.; Yen, R.W.; Gao, J.; Baylin, S.B. De novo methylation of CpG island sequences in human.

Lee, K.W.; Pausova, Z. Cigarette smoking and DNA methylation.

Marsit, C.J.; Houseman, E.A.; Schned, A.R.; Karagas, M.R.; Kelsey, K.T. Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis 2007, 28, 1745–1751. [CrossRef]

Kaur, J.; Demokan, S.; Tripathi, S.C.; Macha, M.A.; Begum, S.; Califano, J.A.; Ralhan, R. Promoter hypermethylation in Indian primary oral squamous cell carcinoma. Int. J. Cancer 2010, 127, 2367–2373. [CrossRef]

Hasegawa, M.; Nelson, H.H.; Peters, E.; Ringstrom, E.; Posner, M.; Kelsey, K.T. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002, 21, 4231–4236. [CrossRef] [PubMed]

Misawa, K.; Mochizuki, D.; Imai, A.; Endo, S.; Mima, M.; Misawa, Y.; Kanazawa, T.; Carey, T.E.; Mineta, H. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer. Oncotarget 2016, 7, 26087–26098. [CrossRef] [PubMed]

Misawa, K.; Mochizuki, D.; Imai, A.; Misawa, Y.; Endo, S.; Mima, M.; Kawasaki, H.; Carey, T.E.; Kanazawa, T. Epigenetic silencing of SALL3 is an independent predictor of poor survival in head and neck cancer. Clin. Epigenet. 2017, 9, 64. [CrossRef] [PubMed]

von Zeidler, S.V.; Miracca, E.C.; Nagai, M.A.; Birman, E.G. Hypermethylation of the p16 gene in normal oral mucosa of smokers. Int. J. Mol. Med. 2004, 14, 807–811. [CrossRef] [PubMed]

Dong, S.M.; Sun, D.J.; Benoit, N.E.; Kuzmin, I.; Lerman, M.I.; Sidransky, D. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin. Cancer Res. 2003, 9, 3635–3640.

Ai, L.; Stephenson, K.K.; Ling, W.; Zuo, C.; Mukunyadzi, P.; Suen, J.Y.; Hanna, E.; Fan, C.Y. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: A promoter methylation and protein expression study in 100 cases. Mod. Pathol. 2003, 16, 944–950. [CrossRef]

Lee, K.W.; Pausova, Z. Cigarette smoking and DNA methylation. Front. Genet. 2013, 4, 132. [CrossRef]

Vertino, P.M.; Yen, R.W.; Gao, J.; Baylin, S.B. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol. Cell. Biol. 1996, 16, 4555–4565. [CrossRef] [PubMed]

Belinsky, S.A.; Nikula, K.J.; Baylin, S.B.; Issa, J.P. Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc. Natl. Acad. Sci. USA 1996, 93, 4045–4050. [CrossRef]

Sharan, R.N.; Mehrotra, R.; Choudhury, Y.; Asotra, K. Association of betel nut with carcinogenesis: Revisit with a clinical perspective. PloS ONE 2012, 7, e42759. [CrossRef] [PubMed]

Ariyawardana, A.; Athukorala, A.D.; Arulanandam, A. Effect of betel chewing, tobacco smoking and alcohol consumption on oral submucous fibrosis: A case-control study in Sri Lanka. J. Oral Pathol. Med. 2006, 35, 197–201. [CrossRef]

Amarasena, N.; Ekanayaka, A.N.; Herath, L.; Miyazaki, H. Association between smoking, betel chewing and gingival bleeding in rural Sri Lanka. J. Clin. Periodontol. 2003, 30, 403–408. [CrossRef]

Tran, T.N.; Liu, Y.; Takagi, M.; Yamaguchi, A.; Fujii, H. Frequent promoter hypermethylation of RASSF1A and p16INK4a and infrequent allelic loss other than 9p21 in betel-associated oral carcinoma in a Vietnamese non-smoking/non-drinking female population. J. Oral Pathol. Med. 2005, 34, 150–156. [CrossRef] [PubMed]

Smith, E.M.; Ritchie, J.M.; Summersgill, K.F.; Klussmann, J.P.; Lee, J.H.; Wang, D.; Haugen, T.H.; Turek, L.P. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. J. Clin. Investig. 2003, 112, 4045–4050. [CrossRef]

Gunasekera, S.K.; Perera, K.A.; Fernando, C.; Udagama, P.V. A shifting paradigm in the aetiology of oral and pharyngeal cancer in Sri Lanka: A case-control study providing serologic evidence for the role of oncogenic HPV types 16 and 18. Infect. Agents Cancer 2015, 10, 12. [CrossRef]
78. Sen, P.; Ganguly, P.; Ganguly, N. Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer. *Oncol. Lett.* 2018, 15, 11–22. [CrossRef]

79. De Freitas Cordeiro-Silva, M.; Stur, E.; Agostini, L.P.; de Podesta, J.R.; de Oliveira, J.C.; Soares, M.S.; Mendonca, E.F.; Gouvea, S.A.; Von Zeidler, S.V.; Louro, I.D. Promoter hypermethylation in primary squamous cell carcinoma of the oral cavity and oropharynx: A study of a Brazilian cohort. *Mol. Biol. Rep.* 2012, 39, 10111–10119. [CrossRef]

80. Leygo, C.; Williams, M.; Jin, H.C.; Chan, M.W.Y.; Chu, W.K.; Grusch, M.; Cheng, Y.Y. DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer. *Dis. Markers* 2017, 2017, 3726595. [CrossRef]

81. Arantes, L.M.; de Carvalho, A.C.; Melendez, M.E.; Centrone, C.C.; Gois-Filho, J.F.; Toporcov, T.N.; Caly, D.N.; Tajara, E.H.; Goloni-Bertollo, E.M.; Carvalho, A.L.; et al. Validation of methylation markers for diagnosis of oral cavity cancer. *Eur. J. Cancer* 2015, 51, 632–641. [CrossRef] [PubMed]

82. Al-Kaabi, A.; van Bockel, L.W.; Pothen, A.J.; Willems, S.M. p16INK4A and p14ARF gene promoter hypermethylation as prognostic biomarker in oral and oropharyngeal squamous cell carcinoma: A review. *Dis. Markers* 2014, 2014, 260549. [CrossRef] [PubMed]

83. Sinha, P.; Bahadur, S.; Thakar, A.; Matta, A.; Maha, M.; Ralph, R.; Gupta, S.D. Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue. *Head Neck* 2009, 31, 1423–1430. [CrossRef] [PubMed]

84. Liu, H.; Liu, X.W.; Dong, G.; Zhou, J.; Liu, Y.; Gao, Y.; Liu, X.Y.; Gu, L.; Sun, Z.; Deng, D. P16 Methylation as an Early Predictor for Cancer Development from Oral Epithelial Dysplasia: A Double-blind Multicentre Prospective Study. *EBioMedicine* 2015, 2, 432–437. [CrossRef] [PubMed]

85. Carvalho, A.L.; Henrique, R.; Jeronimo, C.; Nayak, C.S.; Reddy, A.N.; Hoque, M.O.; Chang, S.; Brait, M.; Jiang, W.W.; Kim, M.M.; et al. Detection of promoter hypermethylation in saliva rinse samples as a biomarker for head and neck squamous cell carcinoma surveillance. *Clin. Cancer Res.* 2011, 17, 4782–4789. [CrossRef]

86. Liang, X.H.; Lewis, J.; Foote, R.; Smith, D.; Kademeni, D. Prevalence and significance of human papillomavirus in oral tongue cancer: The Mayo Clinic experience. *J. Oral Maxillofac. Surg.* 2008, 66, 1875–1880. [CrossRef] [PubMed]

87. Machado, J.; Reis, P.P.; Zhang, T.; Simpson, C.; Xu, W.; Perez-Ordonez, B.; Goldstein, D.P.; Brown, D.H.; Gilbert, R.W.; Gullane, P.J.; et al. Low prevalence of human papillomavirus in oral cavity carcinomas. *Head Neck Oncol.* 2010, 2, 6. [CrossRef] [PubMed]

88. Claus, R.; Wilop, S.; Hielscher, T.; Sonnet, M.; Dahl, E.; Galm, O.; Jost, E.; Plass, C. A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. *Epigenetics* 2012, 7, 772–780. [CrossRef]

89. Shaw, R.J.; Hall, G.L.; Lowe, D.; Liloglou, T.; Field, J.K.; Sloan, P.; Risk, J.M. The role of pyrosequencing in head and neck cancer epigenetics: Correlation of quantitative methylation data with gene expression. *Arch. Otolaryngol. Head Neck Surg.* 2008, 134, 251–256. [CrossRef]

90. Roessler, J.; Lehmann, U. Quantitative DNA Methylation Analysis by Pyrosequencing(R). *Methods Mol. Biol.* 2015, 1315, 175–188.

91. Delaney, C.; Garg, S.K.; Yung, R. Analysis of DNA Methylation by Pyrosequencing. *Methods Mol. Biol.* 2015, 1343, 249–264. [PubMed]

92. Mikeska, T.; Bock, C.; El-Maarri, O.; Hubner, A.; Ehrentraut, D.; Schramm, J.; Felsberg, J.; Kahl, P.; Buttner, R.; Pietsch, T.; et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. *J. Mol. Diagn.* 2007, 9, 368–381. [CrossRef] [PubMed]

93. Siegel, E.M.; Riggs, B.M.; Delmas, A.L.; Koch, A.; Hakam, A.; Brown, K.D. Quantitative DNA methylation analysis of candidate genes in cervical cancer. *PLoS ONE* 2015, 10, e0122495. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).